Despite it remains the cornerstone of advanced lung cancer treatment, evidence is that many chemotherapies may drive sarcopenia via NF kappa B activation and protein kinase B (AKT)/mammalian target of rapamycin (mTOR) downregulation leading to loss of myogenesis [36]. This evidence concerns the gene AKT1 and lung cancer.